Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 crossover study of VX-150 analgesic effects in healthy men
NL-OMON46528Phase 1Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VX-150 in pain (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Pain tolerance threshold in experimental pain tests and Pain detection threshold in thermal and capsaicin-induced pain tests. Started Jan 2018; status: active, not recruiting.
02
Drugs
VX-150
03
Conditions
pain
Beyond the preview
Go deeper on NL-OMON46528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46528.